Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management∗∗This article represents one side of a debate on the role of lipid subfractions in cardiovascular risk management; the opposing argument can be found in the accompanying article by Terje R. Pedersen, MD, PhD.
- 1 March 2001
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 87 (5) , 2-7
- https://doi.org/10.1016/s0002-9149(01)01448-5
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Raising low levels of high-density lipoprotein cholesterol is an important target of therapyThe American Journal of Cardiology, 2000
- Coronary Heart Disease: Reducing The RiskCirculation, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Smoking, lipoproteins and coronary heart disease risk Data from the Münster Heart Study (PROCAM)European Heart Journal, 1998
- Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary PreventionEuropean Heart Journal, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)Circulation, 1998
- Beyond LDL Cholesterol ReductionCirculation, 1996
- Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged menThe American Journal of Cardiology, 1996
- Role of triglycerides in coronary artery disease: Lessons from the prospective cardiovascular Münster studyThe American Journal of Cardiology, 1992